TrialFrontiers in immunology2026

Serplulimab combined with bevacizumab and chemotherapy as first-line treatment for recurrent or metastatic cervical cancer (ASTRUM-CC01): a phase II trial.

Hong Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.